EGFR and non-small cell lung carcinoma: In the HERTHENA-Lung01 trial, patritumab deruxtecan was administered at 5.6 mg/kg to 227 patients with previously treated metastatic EGFR-mutated NSCLC divided into two cohorts: Cohort A (dose escalation) and Cohort B (dose expansion) [35].